Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the effect of atomoxetine hydrochloride in treating adults who have attention deficit hyperactivity disorder with comorbid social anxiety disorder

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Atomoxetine Hydrochloride

Criteria

Inclusion Criteria:

• You must be 18 to 65 years old.

• You must have been diagnosed with attention deficit hyperactivity disorder and social anxiety disorder.

• You must be able to visit the doctor's office at least 8 times over a 16 week period.

• You must agree to participate with all tests and examinations that are required for this study.

Exclusion Criteria:

• You are a woman and pregnant or breastfeeding.

• You presently have an acute or unstable medical illness.

• You have a history of allergic reaction to atomoxetine hydrochloride.

• You are taking medications that are not permitted in this study. Your physician will discuss these with you.

• You have taken part in another clinical research trial within the last 30 days or have received treatment with a drug in the last 30 days that has not received regulatory approval.